Targeted Quality Improvement Trial to Improve Post-Discharge VTE
Targeted Quality Improvement Trial to Improve Post-Discharge VTE Chemoprophylaxis After Abdominal and Pelvic Cancer Surgery
Venous thromboembolism (VTE) is the most common preventable cause of death after major abdominal and pelvic cancer surgery, and over one-third of events occur after discharge. National guidelines recommend extended post-discharge chemoprophylaxis, but hospital adherence varies widely. This observational study has two parts. Aim 1 uses interviews, focus groups, and surveys with patients, clinicians, and health system stakeholders to identify barriers and facilitators to implementing a post-discharge VTE chemoprophylaxis quality improvement project. Aim 2 uses retrospective hospital- and population-level data and coincidence analysis to identify hospital performance phenotypes and develop targeted implementation strategies. Findings will inform a separately registered stepped-wedge implementation trial (Aim 3).
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
Aim 1: Semi-structured interviews, focus groups, and electronic surveys will be conducted with patients (n≈20) undergoing abdominal or pelvic cancer surgery, clinicians (n≈20), and health system stakeholders (n≈10). Surveys include study-specific VTE chemoprophylaxis and ordering surveys, the Organizational Readiness to Change Assessment (ORCA), and the Safety Attitudes Questionnaire (SAQ). Interviews are audio-recorded, transcribed, de-identified, and analyzed with hybrid inductive and deductive coding mapped to CFIR domains. Patient eligibility is screened through the medical record; screening data are not linked to survey or interview responses.
Aim 2: De-identified, retrospective hospital- and population-level data (demographics, procedure details, VTE prophylaxis orders, VTE outcomes), obtained through the University of Chicago Center for Research Informatics, will be analyzed using coincidence analysis (CNA) to identify causal pathways, define low- and high-performance hospital phenotypes, and develop targeted implementation strategies. Aim 2 data are kept separate from Aim 1 recruitment data.
This record covers Aims 1 and 2 only. The Aim 3 stepped-wedge trial is registered separately
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago
-
Kontakt:
- Jacob Ryno, MPH
- Telefonnummer: 314-520-0355
- E-mail: jryno@uchicago.edu
-
Ledende efterforsker:
- Ryan P Merkow, MD, MS
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients, clinicians, and health system stakeholders involved in abdominal and pelvic cancer surgery care, plus a retrospective hospital-level dataset.
Beskrivelse
Inclusion Criteria:
- Patients: adults (18-85) undergoing abdominal and/or pelvic cancer surgery; English-speaking
- Clinicians: faculty and fellow physicians, advanced practice providers, physician assistants, medical assistants, dietitians, and social workers in participating surgical service clinics; English-speaking
- Stakeholders: Chief Medical Officer, Chief Information Officer, Chief Quality Officer, or related leadership
Aim 2: records of patients undergoing abdominal or pelvic cancer surgery between 1/1/2006 and 9/16/2025
Exclusion Criteria:
- Non-English-speaking individuals
- Patients not undergoing abdominal or pelvic cancer surgery
- Individuals under 18
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: OTHER
- Tidsperspektiver: OTHER
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Patients
Adults undergoing abdominal or pelvic cancer surgery at the University of Chicago Medical Center, interviewed or surveyed about post-discharge VTE chemoprophylaxis. |
|
Clinicians
Surgeons, advanced practice providers, nurses, and other clinical staff who care for abdominal and pelvic cancer surgery patients, interviewed or surveyed. |
|
Health System Stakeholders
Chief Medical, Information (or Medical Information), and Quality Officers and related leadership, interviewed. |
|
Retrospective Hospital/Patient Dataset (Aim 2)
De-identified, hospital- and population-level records of abdominal and pelvic cancer surgery patients, 2006-2025 |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Barriers and facilitators to post-discharge VTE chemoprophylaxis implementation
Tidsramme: Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.
|
Themes identified from interviews and focus groups, coded and mapped to CFIR domains |
Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Organizational readiness to change (ORCA score)
Tidsramme: Year 1 and 2; Single survey at enrollment.
|
Survey scores, dichotomized as low or high |
Year 1 and 2; Single survey at enrollment.
|
|
Safety and quality culture (SAQ score)
Tidsramme: Year 1 and 2; Single survey at enrollment.
|
Survey scores, dichotomized as low or high. |
Year 1 and 2; Single survey at enrollment.
|
|
VTE chemoprophylaxis ordering patterns
Tidsramme: Year 1 and 2; Single survey at enrollment.
|
Survey responses on type of prophylaxis prescribed, reasoning, and risk factors. |
Year 1 and 2; Single survey at enrollment.
|
|
Hospital performance phenotypes
Tidsramme: Year 3; Following AIM 2 completion.
|
Number and characteristics of low- and high-performance phenotypes identified by coincidence analysis of Aim 1 and retrospective data. |
Year 3; Following AIM 2 completion.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Ryan Merkow, MS, MD, University of Chicago
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IRB25-1360
- R01HL183429 (U.S. NIH-bevilling/kontrakt)
- IRB25-1360 (Anden identifikator: UChicago IRB)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualitative recordings and transcripts will not be shared. De-identified data will be retained in secure University of Chicago storage, and any external sharing would require IRB review
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .